대한약품

023910KOSDAQ

61.0 / 100

Reference Date: 2026-09-08

Financial Score30.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Daehan Pharmaceuticals primarily produces and sells essential pharmaceuticals such as intravenous solutions, ampoules, and OTC products like lens cleaning solutions. In 2024, the company achieved revenue of 204.1 billion won and operating profit of 38 billion won. Through investments in new production lines and automated warehouses, the company has enhanced its large-scale manufacturing and quality control capabilities, maintaining over 80% of sales in hospitals and pharmacies domestically.

Number of Employees

737people

Average Salary

61.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.69Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.53Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

9.60Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

1.31Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.9% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 26,750Won52-week high 31,30052-week low 24,350

1-month return3.0Point

1m -0.93% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
Neutral반기보고서 (2026.06)2026-08-14